Association of serum adiponectin levels with breast cancer risk.

PURPOSE Adiponectin is a peptide hormone secreted from the adipose tissue, affecting the proliferation and insulin sensitivity of various types of cells. Because association of obesity with breast cancer risk is well established, it is possible that adiponectin plays some role in the development of breast cancer. Thus, in the present study, the association of the serum adiponectin levels with breast cancer risk was investigated. EXPERIMENTAL DESIGN A case-control study was conducted on 102 breast cancer patients (cases) and 100 healthy women (controls). The serum adiponectin levels of cases and controls were examined in their association with breast cancer risk after adjustment for the various classical risk factors (family history, age at menarche, parity, body mass index, and so forth). In addition, the relationship between the serum adiponectin levels and the various clinicopathological characteristics of breast cancers was studied. RESULTS Women in the low tertile of serum adiponectin levels were associated with a significantly (P < 0.005) increased risk for breast cancer compared with women in the high tertile [odds ratio (OR), 3.63; 95% confidence interval (CI), 1.61-8.19]. Such an association was observed both in the premenopausal women (OR, 3.46; 95% CI, 0.89-13.50) and in the postmenopausal women (OR, 3.90; 95% CI, 1.23-12.44). The frequency of large (>2 cm) tumors and that of high histological grade (2+3) tumors were significantly (P < 0.005 and P < 0.05, respectively) higher in breast cancer patients in the low tertile of the serum adiponectin levels than those in the high and intermediate tertiles. CONCLUSIONS These results suggest that the low serum adiponectin levels are significantly associated with an increased risk for breast cancer and that tumors arising in women with the low serum adiponectin levels are more likely to show a biologically aggressive phenotype. The association between obesity and breast cancer risk might be partly explained by adiponectin.

[1]  L. Tessitore,et al.  Leptin expression in colorectal and breast cancer patients. , 2000, International journal of molecular medicine.

[2]  G. Clark,et al.  Serum concentrations of total and non‐protein‐bound oestradiol in patients with breast cancer and in normal controls , 1982, International journal of cancer.

[3]  M. Thun,et al.  Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women , 2002, Cancer Causes & Control.

[4]  C. Nagata,et al.  Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan , 1997, Breast Cancer Research and Treatment.

[5]  J. C. Porter,et al.  Identification of the estrogen product of extraglandular aromatization of plasma androstenedione. , 1978, American journal of obstetrics and gynecology.

[6]  K. Yasuda,et al.  Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. , 2002, Biochimica et biophysica acta.

[7]  Y. Nakano,et al.  Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. , 1996, Journal of biochemistry.

[8]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Tai,et al.  Plasma adiponectin levels in overweight and obese Asians. , 2002, Obesity research.

[10]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[11]  A. Oshima,et al.  Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. , 1999, Japanese journal of clinical oncology.

[12]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[13]  P. Porter,et al.  Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma , 2001, Cancer.

[14]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[15]  E. Sterns,et al.  Plasma concentrations of C-19 steroids, estrogens, FSH, LH and prolactin in post-menopausal women with an without breast cancer. , 1981, Oncology.

[16]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[17]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[18]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[19]  P. Strax,et al.  A prospective study of endogenous estrogens and breast cancer in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[20]  Xin Hu,et al.  Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. , 2003, Journal of the National Cancer Institute.

[21]  M. Dieudonné,et al.  Leptin mediates a proliferative response in human MCF7 breast cancer cells. , 2002, Biochemical and biophysical research communications.

[22]  R. Lang,et al.  Radiommunological measurement of leptin in plasma of obese and diabetic human subjects. , 1996, Endocrinology.

[23]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[24]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[25]  T. Key,et al.  Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom) , 2004, Cancer Causes & Control.

[26]  M. Dowsett,et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. , 1997, British Journal of Cancer.

[27]  奥村 三恵.  Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells : Reciprocal involvement of PKC-α and PPAR expression , 2002 .

[28]  J. Ohannesian,et al.  Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. , 1996, The Journal of clinical investigation.

[29]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[30]  Emily White,et al.  Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States) , 2002, Cancer Causes & Control.

[31]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[32]  C. Mantzoros,et al.  Leptin in relation to carcinoma In situ of the breast: A study of pre‐menopausal cases and controls , 1999, International journal of cancer.

[33]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[34]  M. Inoue,et al.  Association of Family History and Other risk factors with Breast Cancer Risk among Japanese Premenopausal and Postmenopausal Women , 2001, Cancer Causes & Control.

[35]  M. Pike,et al.  Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. , 1990, British Journal of Cancer.

[36]  D. Trichopoulos,et al.  Leptin and insulin growth factor I in relation to breast cancer (Greece) , 2000, Cancer Causes & Control.

[37]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.